Compagnie Lombard Odier SCmA’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-800	Closed	-$1K	–	598
2020 Q2	$1K	Hold	800	–	–	﹤0.01%	524
2020 Q1	$1K	Hold	800	–	–	﹤0.01%	496
2019 Q4	$1K	Hold	800	–	–	﹤0.01%	518
2019 Q3	$1K	Hold	800	–	–	﹤0.01%	525
2019 Q2	$1K	Hold	800	–	–	﹤0.01%	521
2019 Q1	$1K	Hold	800	–	–	﹤0.01%	571
2018 Q4	$1K	Hold	800	–	–	﹤0.01%	546
2018 Q3	$2K	Hold	800	–	–	﹤0.01%	550
2018 Q2	$4K	Hold	800	–	–	﹤0.01%	577
2018 Q1	$3K	Hold	800	–	–	﹤0.01%	590
2017 Q4	$2K	Hold	800	–	–	﹤0.01%	630
2017 Q3	$3K	Hold	800	–	–	﹤0.01%	675
2017 Q2	$3K	Hold	800	–	–	﹤0.01%	691
2017 Q1	$3K	Hold	800	–	–	﹤0.01%	707
2016 Q4	$3K	Hold	800	–	–	﹤0.01%	790
2016 Q3	$3K	Hold	800	–	–	﹤0.01%	885
2016 Q2	$3K	Hold	800	–	–	﹤0.01%	877
2016 Q1	$4K	Hold	800	–	–	﹤0.01%	935
2015 Q4	$10K	Buy	+800	New	+$10.7K	﹤0.01%	860

Other funds holding CTIC

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Compagnie Lombard Odier SCmA's CTIC Position: Q3 2020 in Review

Compagnie Lombard Odier SCmA sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2020, closing a stake of 800 shares — an estimated $1K sold.

Compagnie Lombard Odier SCmA first reported a position in CTIC in Q4 2015 and held it in 19 quarters. The position peaked at $10K in Q4 2015. 38 funds tracked by Wall St. Rank hold CTIC as of Q3 2020.

Compagnie Lombard Odier SCmA reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2020 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 800 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2020, an estimated $1K.
Compagnie Lombard Odier SCmA first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2015 and held it in 19 quarters.
Compagnie Lombard Odier SCmA's CTI BioPharma Corp. (DE) Common Stock position peaked at $10K in Q4 2015.
38 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2020.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2020, filed 12 Nov 2020.